QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PFE   39.99 (-0.57%)
PYPL   72.70 (-0.82%)
NFLX   323.52 (-1.26%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PFE   39.99 (-0.57%)
PYPL   72.70 (-0.82%)
NFLX   323.52 (-1.26%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PFE   39.99 (-0.57%)
PYPL   72.70 (-0.82%)
NFLX   323.52 (-1.26%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PFE   39.99 (-0.57%)
PYPL   72.70 (-0.82%)
NFLX   323.52 (-1.26%)
NASDAQ:KZR

Kezar Life Sciences - KZR Stock Forecast, Price & News

$3.21
-0.34 (-9.58%)
(As of 03/28/2023 12:00 AM ET)
Add
Compare
Today's Range
$3.20
▼
$3.66
50-Day Range
$3.35
▼
$7.31
52-Week Range
$3.19
▼
$17.87
Volume
3.45 million shs
Average Volume
806,204 shs
Market Capitalization
$227.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.33

Kezar Life Sciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
471.1% Upside
$18.33 Price Target
Short Interest
Bearish
6.91% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
0.31mentions of Kezar Life Sciences in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$1.71 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.18) to ($1.32) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.12 out of 5 stars

Medical Sector

477th out of 1,002 stocks

Pharmaceutical Preparations Industry

225th out of 488 stocks

See Top Rated MarketRank™ Stocks Here

KZR stock logo

About Kezar Life Sciences (NASDAQ:KZR) Stock

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer. Its product pipeline includes KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.

Receive KZR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kezar Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

KZR Stock News Headlines

March 22, 2023 | americanbankingnews.com
Research Analysts Offer Predictions for Kezar Life Sciences, Inc.'s Q1 2023 Earnings (NASDAQ:KZR)
March 21, 2023 | americanbankingnews.com
Kezar Life Sciences, Inc. (NASDAQ:KZR) to Post Q2 2023 Earnings of ($0.28) Per Share, William Blair Forecasts
March 28, 2023 | Weiss Ratings (Ad)
Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
March 19, 2023 | americanbankingnews.com
HC Wainwright Reaffirms "Buy" Rating for Kezar Life Sciences (NASDAQ:KZR)
March 18, 2023 | americanbankingnews.com
Kezar Life Sciences' (KZR) "Market Perform" Rating Reiterated at William Blair
March 18, 2023 | americanbankingnews.com
Kezar Life Sciences, Inc. (NASDAQ:KZR) Expected to Earn Q1 2023 Earnings of ($0.29) Per Share
March 16, 2023 | msn.com
William Blair Downgrades Kezar Life Sciences (KZR)
March 16, 2023 | seekingalpha.com
Kezar sheds 14% after R&D event as William Blair downgrades
March 28, 2023 | The Oxford Club (Ad)
My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
March 14, 2023 | finance.yahoo.com
Kezar Life Sciences Reports Fourth Quarter and Year End 2022 Financial Results and Provides Business Update
March 13, 2023 | finance.yahoo.com
Kezar Life Sciences to Change Virtual R&D Day Date to March 15, 2023
March 6, 2023 | finance.yahoo.com
Kezar Life Sciences to Host Virtual R&D Day on March 22, 2023
March 1, 2023 | finance.yahoo.com
Kezar Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference
February 23, 2023 | seekingalpha.com
KZR Kezar Life Sciences, Inc.
January 4, 2023 | finance.yahoo.com
Kezar Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 3, 2023 | markets.businessinsider.com
Wells Fargo Reaffirms Their Buy Rating on Kezar Life Sciences (KZR)
November 16, 2022 | seekingalpha.com
Kezar Life Sciences: Mid-Term Growth Levers Heavily Discounted, Reduce To Hold
November 14, 2022 | finance.yahoo.com
Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at the American College of Rheumatology Convergence 2022
November 10, 2022 | finance.yahoo.com
Kezar Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update
November 3, 2022 | finance.yahoo.com
Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at ASN’s Kidney Week 2022 Annual Meeting
October 14, 2022 | finance.yahoo.com
Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American Society of Nephrology’s Kidney Week 2022 Annual Meeting
October 4, 2022 | forbes.com
Kezar Life Sciences
October 3, 2022 | msn.com
Why Kezar Life Sciences Shares Are Volatile After Hours
October 3, 2022 | finance.yahoo.com
Kezar Life Sciences Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune Hepatitis
September 29, 2022 | finance.yahoo.com
Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022
September 20, 2022 | nasdaq.com
Is Kezar Life Sciences (NASDAQ:KZR) Using Debt In A Risky Way?
September 1, 2022 | finance.yahoo.com
Kezar Life Sciences to Participate in Three Upcoming Investor Conferences
See More Headlines
Receive KZR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kezar Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

KZR Company Calendar

Last Earnings
11/09/2021
Today
3/28/2023
Next Earnings (Estimated)
5/11/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KZR
CUSIP
N/A
CIK
1645666
Web
www.kezarlifesciences.com
Phone
(650) 822-5600
Fax
N/A
Employees
56
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$18.33
High Stock Price Forecast
$21.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+471.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.01)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-68,240,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-25.21%
Return on Assets
-23.26%

Debt

Debt-to-Equity Ratio
0.04
Current Ratio
25.98
Quick Ratio
25.98

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.95 per share
Price / Book
0.81

Miscellaneous

Outstanding Shares
70,800,000
Free Float
65,281,000
Market Cap
$227.27 million
Optionable
Not Optionable
Beta
0.25

Key Executives

  • John Fowler
    Chief Executive Officer & Director
  • Christopher J. Kirk
    President, Director & Chief Scientific Officer
  • Michael Wolfe
    Director-Finance & Business Operations
  • Marc L. BelskyMarc L. Belsky
    Chief Financial Officer & Secretary
  • Noreen Roth Henig
    Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













KZR Stock - Frequently Asked Questions

Should I buy or sell Kezar Life Sciences stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kezar Life Sciences in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" KZR shares.
View KZR analyst ratings or view top-rated stocks.

What is Kezar Life Sciences' stock price forecast for 2023?

3 brokerages have issued 1 year price targets for Kezar Life Sciences' shares. Their KZR share price forecasts range from $14.00 to $21.00. On average, they expect the company's stock price to reach $18.33 in the next twelve months. This suggests a possible upside of 471.1% from the stock's current price.
View analysts price targets for KZR or view top-rated stocks among Wall Street analysts.

How have KZR shares performed in 2023?

Kezar Life Sciences' stock was trading at $7.04 at the start of the year. Since then, KZR stock has decreased by 54.4% and is now trading at $3.21.
View the best growth stocks for 2023 here.

Are investors shorting Kezar Life Sciences?

Kezar Life Sciences saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 4,890,000 shares, an increase of 13.2% from the February 28th total of 4,320,000 shares. Based on an average trading volume of 714,700 shares, the short-interest ratio is presently 6.8 days.
View Kezar Life Sciences' Short Interest.

When is Kezar Life Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our KZR earnings forecast.

How were Kezar Life Sciences' earnings last quarter?

Kezar Life Sciences, Inc. (NASDAQ:KZR) posted its earnings results on Tuesday, November, 9th. The company reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by $0.02.

What ETFs hold Kezar Life Sciences' stock?

ETFs with the largest weight of Kezar Life Sciences (NASDAQ:KZR) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), ALPS Medical Breakthroughs ETF (SBIO) and SPDR S&P Biotech ETF (XBI).Direxion Daily S&P Biotech Bull 3x Shares (LABU).

What other stocks do shareholders of Kezar Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kezar Life Sciences investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Pfizer (PFE), VYNE Therapeutics (vyne), Dynavax Technologies (DVAX), Gilead Sciences (GILD), AbbVie (ABBV), Aldeyra Therapeutics (ALDX) and Exelixis (EXEL).

When did Kezar Life Sciences IPO?

(KZR) raised $70 million in an IPO on Thursday, June 21st 2018. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair served as the underwriters for the IPO.

What is Kezar Life Sciences' stock symbol?

Kezar Life Sciences trades on the NASDAQ under the ticker symbol "KZR."

Who are Kezar Life Sciences' major shareholders?

Kezar Life Sciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Avidity Partners Management LP (9.92%), Millennium Management LLC (4.24%), Sphera Funds Management LTD. (1.91%), JPMorgan Chase & Co. (1.57%), Geode Capital Management LLC (1.43%) and Granahan Investment Management LLC (1.01%). Insiders that own company stock include Equal Talent Investments Ltd, Franklin M Berger, Michael Kauffman and Morningside Venture Investment.
View institutional ownership trends.

How do I buy shares of Kezar Life Sciences?

Shares of KZR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kezar Life Sciences' stock price today?

One share of KZR stock can currently be purchased for approximately $3.21.

How much money does Kezar Life Sciences make?

Kezar Life Sciences (NASDAQ:KZR) has a market capitalization of $227.27 million. The company earns $-68,240,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis.

How can I contact Kezar Life Sciences?

Kezar Life Sciences' mailing address is 4000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.kezarlifesciences.com. The company can be reached via phone at (650) 822-5600 or via email at ceconomides@kezarbio.com.

This page (NASDAQ:KZR) was last updated on 3/28/2023 by MarketBeat.com Staff